Quantitative Imaging: A hospital physicist s perspective James Scuffham
|
|
- Melvin Jefferson
- 6 years ago
- Views:
Transcription
1 Quantitative Imaging: A hospital physicist s perspective James Scuffham Clinical Scientist, Royal Surrey County Hospital NHS Foundation Trust Associate Tutor, University of Surrey
2 Background The Royal Surrey is a District General Hospital in South East England serving a population of 320,000. It incorporates St Luke s Cancer Centre, which serves a population of 1.2 million for cancer services
3 Background The Nuclear Medicine department at RSCH has three gamma cameras (1 SPECT/CT), and two ward rooms for molecular radiotherapy Nuc Med is supported by a team of 8 physicists who also provide Medical Physics support to a further 7 diagnostic imaging departments and 5 mobile PET/CT units. Molecular Radiotherapy Procedures at RSCH include: I-131 for thyroid cancer I-131 for thyrotoxicosis Ra-223 for skeletal metastases from prostate cancer Y-90 microspheres for hepatic malignancies Lu-177 DOTATATE for neuroendocrine cancer [Y-90 radiosynoviorthesis] [Sr-89 / Sm-153 for painful bone metastases]
4 Why am I here? RSCH was a collaborator on MetroMRT and is an unfunded clinical partner in MRTDosimetry We have two joint PhD students with NPL and the University of Surrey University of Surrey is a strategic partner with NPL
5 But what about dosimetry? My confession. Routine organ-level dosimetry is not done at RSCH (except for Y-90 microspheres). But. We are striving towards it. Barriers? Lack of clinical interest/confidence (no trial evidence) Lack of guidelines on how to do it properly Gamma camera availability Logistics (patient transfer; staff dose concerns) Time Cost / Reimbursement
6 What about quantitative imaging? We have established quantitative imaging protocols for: Lu-177 (through Jill Merrett s PhD and MetroMRT) and I-131 (through the SELIMETRY study)
7 I-131: The SELIMETRY Study Multi-centre trial in the UK assessing the efficacy of selumetinib followed by radioiodine in iodine refractory thyroid cancer. Ho et al, NEJM 2013; 368: /20 patients demonstrated increased uptake on Iodine-124 PET Dosimetry performed on I-124 PET 8/20 patients reached threshold of 20Gy to iodine-avid lesions
8 SELIMETRY Dosimetry Pathway Baseline I-123 Scan Selumetinib Repeat I-123 Scan I-131 Therapy I-131 Dosimetry Scans rhtsh stimulation Confirm iodine refractory disease 75mg bd for 4 weeks rhtsh stimulation Check for iodine uptake If uptake is confirmed, proceed to dosimetry SPECT/CT at 5, 24, 48 and 72 hours Continue on selumetinib rhtsh stimulation 5.5GBq I-131 NaI SPECT/CT at 24, 48, 72 and 144 hours SELIMETRY trial includes exploratory objectives to investigate the role of lesion dosimetry using I-123 SPECT/CT to predict response to I-131 therapy 60 patients to be recruited over 4 years Eight sites in UK
9 SELIMETRY Acquisition Parameters Parameter I-123 I-131 Collimator Medium-energy general High-energy general purpose purpose (MEGP) (HEGP) Peak Energy window (20%) 159 kev ± 10% 364 kev ± 10% Low Scatter Energy window (6%) 138 kev ± 3% 318 kev ± 3% High Scatter Energy window (6%) 180 kev ± 3% 413 kev ± 3% Matrix 128 x 128 SPECT movement Body Contour (or radius as close to phantom as possible) Projections 72 (5 /projection) Time per projection 60 s* CT Standard low dose protocol Reconstruction OSEM, 40it, 4sub, no post-filtering, TEW + CTAC
10 SELIMETRY: Site set-up The core laboratory is the Royal Marsden Hospital, and RSCH acted as the pilot site for the Quantitative Imaging protocol development and testing. Characterisation of GE Optima 640 SPECT/CT system at RSCH: Partial Volume Deadtime
11 SELIMETRY: Calibration Factors Six fillable cylindrical inserts of increasing volume: 1x1cm = 0.8ml 2x2cm = 6.3ml 3x3cm = 21.0ml 4x4cm = 50.7ml 5x5cm = 98.0ml 6.3x6.3cm = 196.3ml Scan together inside NEMA IEC body phantom at 8cm radius Prepared with 100MBq I-123 NaI diluted in 400ml with 1g Potassium Iodide and 1g Sodium Thiosulphate Repeat with 100MBq I-131
12 SELIMETRY: RSCH Results 1 I-123 I-131 RC fit 1 / x Radioiodine 123 I I
13 SELIMETRY: Dead time characterisation Jaszczak cylinder phantom half-filled with water and with I-131 activity increasing from 20MBq to 2800MBq (added from two 4ml stock solutions of 100MBq/ml and 600MBq/ml) 100k counts acquired for each activity Test in normal and fast modes
14 SELIMETRY: RSCH Results 2 With fast mode enabled, dead time losses are observed for activities > 1.6GBq (37 kcps) and are <12% up to 2.8GBq (60kcps) Curves extrapolated from points up to 40MBq to estimate true counts, n. Paralysable model assumed: m = n exp(-nτ)
15 SELIMETRY: Quality Control Requirements Check Within preceding Limits Energy peak position month - Integral CFOV < 4% 123 I intrinsic (20 million count) uniformity month (allow time to Differential CFOV < 3% correct artefacts where 131 I intrinsic (20 million count) uniformity necessary) No significant uniformity artefacts 99m Tc intrinsic (20 million count) uniformity week COR for both the MEGP and HEGP collimators month SPECT/CT system alignment checks month Within local limits Extrinsic HEGP and MEGP floods week QC of radionuclide calibrator day
16 What we ve learned Multi-centre standardisation of quantitative imaging protocol is feasible Need to check high count-rate mode is set up properly by manufacturer before doing calibrations more on this later (Nick Bates) Artefacts in PVC curves may occur if sources are not adequately spaced; investigating significance Doses to staff doing dead time calibrations do not exceed occupational constraints but could be further reduced with use of mobile shielding
17 Conclusions Quantitative imaging & dosimetry sub-study of SELIMETRY using I-123 SPECT/CT as a surrogate for I-131 The trial will help to make dosimetry visible to clinicians The trial will generate valuable clinical trial evidence for dosimetry Along with standardisation of metrology protocols, this is the key to the successful implementation of dosimetry in MRT
18 Acknowledgements Rebecca Gregory, Glenn Flux Royal Marsden Hospital Jill Merrett, Andy Fenwick National Physical Laboratory Hannah Wiedner and the meeting organisers for the invitation to speak
METROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY. Glenn Flux
METROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY Glenn Flux Head of Radioisotope Physics Royal Marsden Hospital & Institute of Cancer Research Sutton UK CGPM 2018 glenn.flux@icr.ac.uk Overview
More informationQuantitative Theranostics in Nuclear Medicine
Quantitative Theranostics in Nuclear Medicine M. Lassmann Klinik und Poliklinik für Nuklearmedizin Direktor: Prof. Dr. A. Buck Contents What is Theranostics? Potential Targets Basic Principles of Quantitative
More informationPublishable Summary for 15HLT06 MRTDosimetry Metrology for clinical implementation of dosimetry in molecular radiotherapy
Publishable Summary for 15HLT06 MRTDosimetry Metrology for clinical implementation of dosimetry in molecular radiotherapy Overview The overall aim of this project is to provide the metrology for the clinical
More informationApplication of 3D Printing to Molecular Radiotherapy Phantoms. Nick Calvert Nuclear Medicine Group The Christie NHS Foundation Trust, Manchester
Application of 3D Printing to Molecular Radiotherapy Phantoms Nick Calvert Nuclear Medicine Group The Christie NHS Foundation Trust, Manchester Molecular Radiotherapy Radionuclide administered to patient
More informationTheragnostics for bone metastases. Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK
Theragnostics for bone metastases Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK NPL 2015 Ra-223 Biodistribution & dosimetry Ra-223: 11.4 days half-life, range of 100 µm Six
More informationCalculation methods in Hermes Medical Solutions dosimetry software
Calculation methods in Hermes Medical Solutions dosimetry software Helena McMeekin MSc. Clinical Applications Scientist, Hermes Medical Solutions MRTDosimetry Scientific Workshop The Principals and Clinical
More informationPublishable JRP Summary Report for JRP HLT11 MetroMRT Metrology for Molecular Radiotherapy Background
Publishable JRP Summary Report for JRP HLT11 MetroMRT Metrology for Molecular Radiotherapy Background The medical treatment modality of molecular radiotherapy (MRT), or nuclear medicine therapy, has been
More informationIndividualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)
Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy) FMU/ICRP workshop 2017 Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK ICRP Task Group 101
More informationBackground. New Cross Hospital is a 700 bed DGH located in central England
Background New Cross Hospital is a 700 bed DGH located in central England Regional Heart & Lung centre opened in 2005 Covering the Black Country (Population >1,000,000) Nuclear Medicine Department Single
More informationFacilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017
Facilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017 CANM ANNUAL SCIENTIFIC MEETING APRIL 20-23, 2017 TORONTO, ONTARIO I do not have a financial interest, arrangement or affiliation
More informationRadiation Detection and Measurement
Radiation Detection and Measurement Range of charged particles (e.g.,!: µm; ": mm) Range of high energy photons (cm) Two main types of interactions of high energy photons Compton scatter Photoelectric
More informationAustin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)
Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate) Overview Ga-68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (sstr2). It binds to cells that express
More informationPrecision of pre-sirt predictive dosimetry
International Course on THERANOSTICS AND MOLECULAR RADIOTHERAPY Precision of pre-sirt predictive dosimetry Hugo Levillain Department of Nuclear Medicine Medical Physics Jules Bordet Institute, Université
More informationErasmus Experience. Lu-DOTA-octreotate PRRT
Erasmus Experience 177 Lu-DOTA-octreotate PRRT Mark Konijnenberg Erasmus MC, Rotterdam, Netherlands METRO/MRT meeting 2015, NPL, Teddington Leading questions? 1. For which MRT procedure dosimetry is used?
More informationThe IAEA BSS and development of an international dosimetry protocol
The BSS and development of an international dosimetry protocol MetroMRT 3 rd Workshop National Physical Laboratory, Teddington, UK 20-21 April 2015 Gian Luca POLI International Atomic Energy Agency Dosimetry
More informationCHARACTERIZATION OF A SMALL FIELD GAMMA CAMERA FOR THYROID SCINTISCANNING
CHARACTERIZATION OF A SMALL FIELD GAMMA CAMERA FOR THYROID SCINTISCANNING E. Richetta Supervisor: M. I. Ferrero Co-examiner: G. Scielzo Examiner: G. Perno Aim Thyroid scintiscanning is a diagnostic methodology
More informationCase 4: Disseminated bone metastases from differentiated follicular thyroid cancer
Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer Giuliano Mariani Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa (Italy) Disseminated bone
More informationA. DeWerd. Michael Kissick. Larry. Editors. The Phantoms of Medical. and Health Physics. Devices for Research and Development.
Larry Editors A. DeWerd Michael Kissick The Phantoms of Medical and Health Physics Devices for Research and Development ^ Springer Contents 1 Introduction to Phantoms of Medical and Health Physics 1 1.1
More informationLu-DOTATATE PRRT dosimetry:
177 Lu-DOTATATE PRRT dosimetry: From theory to practice Silvano Gnesin Medical Physics department Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland Gwennaëlle Marin Medical
More informationTypical PET Image. Elevated uptake of FDG (related to metabolism) Lung cancer example: But where exactly is it located?
Typical PET Image Elevated uptake of FDG (related to metabolism) Lung cancer example: But where exactly is it located? PET/CT Oncology Imaging Anatometabolic fusion images are useful in the management
More informationEN TERAPIA METAByLICA NO ESTrNDAR CON 177 Lu, 90 Y y 223 Ra
Jornada científica RADIOFuSICA DE LA DOSIMETRuA INTERNA EN LOS PROCEDIMIENTOS TERAPÉUTICOS CON RADIOFrRMACOS DOSIMETRIA FuSICA Y CLuNICA EN TERAPIA METAByLICA NO ESTrNDAR CON 177 Lu, 90 Y y 223 Ra Pablo
More informationAustin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF)
Austin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF) Overview Indication Sodium Fluoride F18 injection is a radioactive diagnostic agent for positron emission
More informationPhysical Bases : Which Isotopes?
Physical Bases : Which Isotopes? S. Gnesin Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland 1/53 Theranostic Bruxelles, 2 Octobrer 2017 Theranostic : use of diagnostic
More information8/1/2017. Disclosures. Outline. SAM Imaging Education Course 90Y-Microsphere Therapy: Emerging Trends and Future Directions
SAM Imaging Education Course Y-Microsphere Therapy: Emerging Trends and Future Directions Matt Vanderhoek, PhD Henry Ford Health System, Detroit, MI Vanessa Gates, MS Northwestern University, Chicago,
More informationChapter 19: Radionuclide Therapy
Chapter 19: Radionuclide Therapy Slide set of 40 slides based on the chapter authored by G. Flux and Y. Du of the publication (ISBN 978 92 0 143810 2): Nuclear Medicine Physics: A Handbook for Teachers
More informationMPI Overview. Artifacts and Pitfalls in MPI. Acquisition and Processing. Peeyush Bhargava MD, MBA
Artifacts and Pitfalls in MPI MPI Overview Peeyush Bhargava MD, MBA www.nuclearmd.com ~ 40% of all Nuclear Medicine Procedures ~ 9 million procedures every year in US >95% are SPECT,
More informationOutline. Lifetime Attributable Risk 10 mgy in 100,000 exposed persons (BEIR VII 2006) SPECT/CT and PET/CT Dosimetry
SPECT/CT and PET/CT Dosimetry Lifetime Attributable Risk 10 mgy in 100,000 exposed persons (BEIR VII 2006) All Solid Tumors Leukemia Frederic H. Fahey DSc Male Female Male Female Children s Hospital Boston
More informationAustin Radiological Association Nuclear Medicine Procedure THYROID UPTAKE MEASUREMENT (I-123 or I-131 as Sodium Iodide)
Austin Radiological Association Nuclear Medicine Procedure THYROID UPTAKE MEASUREMENT (I-123 or I-131 as Sodium Iodide) Overview Indications The Thyroid Uptake Measurement measures the metabolic activity
More information3D Printed Phantoms for MRT Dosimetry
3D Printed Phantoms for MRT Dosimetry Dr. Andrew Robinson Nuclear Physics Group, The University of Manchester Christie Medical Physics and Engineering, The Christie NHS Foundation Trust BIR/IDUG: The Future
More informationAustin Radiological Association Nuclear Medicine Procedure PROSTATE CANCER STUDY (In-111-Capromab Pendetide [ProstaScint ])
Austin Radiological Association Nuclear Medicine Procedure PROSTATE CANCER STUDY (In-111-Capromab Pendetide [ProstaScint ]) Overview Indications The Prostate Cancer Study with an indium-111 labeled murine
More informationNuclear Medicine and PET. D. J. McMahon rev cewood
Nuclear Medicine and PET D. J. McMahon 150504 rev cewood 2018-02-15 Key Points Nuclear Medicine and PET: Imaging: Understand how Nuc Med & PET differ from Radiography & CT by the source of radiation. Be
More informationAustin Radiological Association BRAIN AMYLOID STUDY (F-18-Florbetapir)
Austin Radiological Association BRAIN AMYLOID STUDY (F-18-Florbetapir) Overview The Brain Amyloid Study with F-18-florbetapir depicts the extracellular deposition of B- amyloid (Aβ) peptides (or plaques
More informationVerification of Advanced Radiotherapy Techniques
Verification of Advanced Radiotherapy Techniques Catharine Clark, PhD Principal Research Scientist Radiation Dosimetry group and Consultant Clinical Scientist Royal Surrey County Hospital 2 nd December
More informationA method to measure the absorbed dose of the thyroid during I-131 therapy, using a collar detector system and a SPECT acquisition
A method to measure the absorbed dose of the thyroid during I-131 therapy, using a collar detector system and a SPECT acquisition Koen van Gils and Peter Brinks Department of Medical Physics, St Antonius
More informationDevelopment of a portable gamma imaging system for absorbed radia4on dose control in targeted radionuclide therapy
Development of a portable gamma imaging system for absorbed radia4on dose control in targeted radionuclide therapy PhD Student Group IIRIC (Instrument. & Imagerie Radio-isotopique Clinique) L. Ménard,
More informationIART and EBRT, an innovative approach
External beam radiotherapy and nuclear medicine therapy: which kind of integration? Mahila Ferrari mahila.ferrari ferrari@ieo.it A different NM and RT integration... Radionuclide therapy combined to EBRT
More informationY-PET versus 90 Y-Bremsstrahlung SPECT
90 Y-PET versus 90 Y-Bremsstrahlung SPECT First 90 Y microspheres injected intra-arterially imaging 90 Y TOF PET/CT 198 Au rays scan 90 Y bremsstrahlung scan Lhommel et al. 2009 Simon and Feitelberg 1967
More informationKEYWORDS: nuclear medicine; gamma camera; radiopharmaceutical activities.
Radiopharmaceutical Activities Administered for Diagnostic Procedures in Nuclear Medicine in the First Six Months of the Gamma Camera Use in the Clinical Center of Montenegro - Podgorica Nevenka Antovic
More informationOptimization of a routine method for bone marrow dose estimation in
Optimization of a routine method for bone marrow dose estimation in 177 Lu-EDTMP therapy- Experience in Uruguay. Teran. M 1, Paolino.A 2, Coppe.F 2, Nuñez M 2, Hermida J C 2, Gaudiano.J 2 1 Cátedra de
More informationNuclear Medicine: Basics to therapy
Nuclear Medicine: Basics to therapy RCP Medical careers day Dr Sabina Dizdarevic MD MSc PhD FRCP Dr Deena Neriman MBBS FRCR Ms Charlotte Weston CEO BNMS On behalf of the British Nuclear Medicine Society
More informationIAEA activities in the field of dosimetry for Radiopharmaceutical Therapy
IAEA activities in the field of dosimetry for Radiopharmaceutical Therapy Gian Luca Poli IAEA Dosimetry and Medical Radiation Physics section e-mail: G.L.Poli@iaea.org European Workshop on Quantitative
More informationInternational Atomic Energy Agency Department of Technical Cooperation And Nuclear Medicine and Diagnostic Imaging Section Division of Human Health
International Atomic Energy Agency Department of Technical Cooperation And Nuclear Medicine and Diagnostic Imaging Section Division of Human Health RAS6074 RAS6074 Improving Quality of Life of Cancer Patients
More informationI-123 Thyroid Scintigraphy
APPROVED BY: Director of Radiology Page 1 of 6 I-123 Thyroid Scintigraphy Primary Indications: Thyroid scintigraphy with I-123 is indicated to evaluate thyroid morphology and global and/or regional function
More informationRadiobiological modelling applied to Unsealed Source (radio) Therapy
Radiobiological modelling applied to Unsealed Source (radio) Therapy Alan E. Nahum Physics Department Clatterbridge Cancer Centre NHS Foundation Trust Bebington, Wirral CH63 4JY UK alan.nahum@clatterbridgecc.nhs.uk
More informationAustin Radiological Association Nuclear Medicine Procedure WHITE BLOOD CELL MIGRATION STUDY (In-111-WBCs, Tc-99m-HMPAO-WBCs)
Austin Radiological Association Nuclear Medicine Procedure WHITE BLOOD CELL MIGRATION STUDY (In-111-WBCs, Tc-99m-HMPAO-WBCs) Overview Indications The White Blood Cell Migration Study demonstrates the distribution
More informationJoint ICTP-IAEA Advanced School on Internal Dosimetry. Trieste, April 2010
Joint ICTP-IAEA Advanced School on Internal Dosimetry Trieste, 12-16 April 2010 Dosimetry in PRRT: what for Dosimetry has the purpose to address %&!"# '!&!"#!(%)* $ *!$+ Most Used Radiopeptides for PRRT
More informationDollars and Sense: Are We Overshielding Imaging Facilities? Part 2
Disclosure Dollars and Sense: Are We Overshielding Imaging Facilities? Part 2 Bryon M. Murray, M.S., DABR Paid consultant to NELCO Worldwide Owner, CEO ZapIT! Medical Objectives Understand methods for
More informationTheranostics in Nuclear Medicine
Theranostics in Nuclear Medicine Patrick FLAMEN, MD, PhD Head Nuclear Medicine Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) n Theranostics in Nuclear Medicine n A form of (nuclear) diagnostic
More informationA Snapshot on Nuclear Cardiac Imaging
Editorial A Snapshot on Nuclear Cardiac Imaging Khalil, M. Department of Physics, Faculty of Science, Helwan University. There is no doubt that nuclear medicine scanning devices are essential tool in the
More informationAtoms for Health. Atoms for Health The. Atoms for Health - Division of Nuclear Health - Dept of Nuclear Aplications P Andreo DIR-NAHU 1
International Atomic Energy Agency Atoms for Health The human side of nuclear applications NUCLEAR APPLICATIONS IN HEALTH A UNIQUE MANDATE OF THE UN SYSTEM The Agency shall seek to accelerate and enlarge
More informationInternal Dosimetry of Human Brain for 99m tc and 131 I Using Nuclear Imaging in Bangladesh
Sri Lankan Journal of Physics, Vol. 6 (2005) 33-41 Institute of Physics - Sri Lanka Internal Dosimetry of Human Brain for 99m tc and 131 I Using Nuclear Imaging in Bangladesh M. M. Alam a, M. I. Kabir
More informationBasics of nuclear medicine
Basics of nuclear medicine Prof. dr. Davor Eterović Prof. dr. Vinko Marković Radioisotopes are used both in diagnostics and in therapy Diagnostics gamma emitters are used since gamma rays can penetrate
More informationPhysics of MBI (~10 slides)
Physics of MBI (~10 slides) Molecular Breast Imaging (MBI) physics and performance testing JW Hugg, BR Simrak, PD Smith, BE Patt Gamma Medica, Inc., Northridge, CA Molecular Breast Imaging (MBI) is an
More informationStandardization of Radiopharmaceutical Dosimetry
Standardization of Radiopharmaceutical Dosimetry Jonathon A. Nye, PhD Department of Radiology and Imaging Sciences Emory University SEAAPM 2011 Myrtle Beach, SC Review of Dosimetry Nomenclature Dose Gray
More informationDosimetry (Dose Estimation) of Internal Emitters. Outline. For Radiation Effects, is Dose the only Answer? Estimation of Dose and not Dosimetry
Dosimetry (Dose Estimation) of Internal Emitters. Lawrence E. Williams, PhD City of Hope National Medical Center Duarte CA 91010 lwilliams@coh.org Outline 1. Dose Estimation Formula D = S*Ã 2. Determination
More informationDiagnostic 131 I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer
European Journal of Endocrinology (2004) 150 649 653 ISSN 0804-4643 CLINICAL STUDY Diagnostic 131 I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer Henry Taylor,
More informationClinical Implementation of patient-specific dosimetry, comparison with absorbed fraction-based method
Clinical Implementation of patient-specific dosimetry, comparison with absorbed fraction-based method George Sgouros, Ph.D. Russell H. Morgan Dept of Radiology & Radiological Science Johns Hopkins University,
More informationThe Effect of Administered Activity on Patient Radiation dose and Image Quality in SPECT at Korle-Bu Teaching Hospital
2017 IJSRST Volume 3 Issue 1 Print ISSN: 2395-6011 Online ISSN: 2395-602X Themed Section: Science and Technology The Effect of Administered Activity on Patient Radiation dose and Image Quality in SPECT
More informationCalculation of Effective Doses for Radiotherapy Cone-Beam CT and Nuclear Medicine Hawkeye CT Laura Sawyer
Calculation of Effective Doses for Radiotherapy Cone-Beam CT and Nuclear Medicine Hawkeye CT Laura Sawyer Department of Medical Physics and Bioengineering, Royal United Hospital, Bath Overview Varian Acuity
More informationPalliative treatment of bone metastases with samarium-153
APPROVED BY: Z. Yang Page 1 of 5 Palliative treatment of bone metastases with samarium-153 Primary Indications: Rationale: To treat bone pain resulting from osteoblastic metastases as defined by bone scan.
More informationCatharine Clark NPL, Royal Surrey County Hospital and RTTQA
Catharine Clark NPL, Royal Surrey County Hospital and RTTQA Background Historically UK has been relatively independent of the rest of the world in audit NPL PSDL International intercomparison for reference
More informationMonitoring of iodine-125 and iodine-131 in thyroid of individuals in nuclear medicine centers of North West provinces of Iran
Iran. J. Radiat. Res., 2004; 2 (3): 141-147 Monitoring of iodine-125 and iodine-131 in thyroid of individuals in nuclear medicine centers of North West provinces of Iran G.H. Heravi, H. Garshasbi *, J.
More informationSIRT in Neuroendocrine Tumors
SIRT in Neuroendocrine Tumors Marnix G.E.H. Lam, MD PhD Professor of Nuclear Medicine AVL Amsterdam UMC Utrecht ENETS Center of Excellence, The Netherlands Disclosure of speaker s interests Consultant
More informationUWE has obtained warranties from all depositors as to their title in the material deposited and as to their right to deposit such material.
King, S. (2010) SPECT/CT: A clinical testament. In: Hybrid Imaging Knowledge Exchange Event, UWE, Bristol, UK, 7 December 2010. Available from: http://eprints.uwe.ac.uk/25183 We recommend you cite the
More informationSORAMIC: NM Procedures
: NM Procedures J. Ruf Klinik für Radiologie und Nuklearmedizin : NM Procedures Evaluation - 99m Tc MAA Scintigraphy Lung shunt assessment Treatment activity determination Therapy - 90 Y-SIR-Spheres Procedure
More informationThyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma.
ORIGINAL ARTICLE Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma. Md. Sayedur Rahman Miah, Md. Reajul Islam, Tanjim Siddika Institute of Nuclear Medicine & Allied Sciences,
More informationDosimetry in Targeted Radionuclide Therapy: The Bad Berka Dose Protocol Practical Experience
10.5005/jp-journals-10028-1058 REVIEW ARTICLE Dosimetry in Targeted Radionuclide Therapy: The Bad Berka Dose Protocol Practical Experience Christiane Schuchardt, Harshad Kulkarni, Carolin Zachert, Richard
More informationImpact of the counts density of calibration image and the image reconstruction parameters in 131 I SPECT image quantification
BJRS BRAZILIAN JOURNAL OF RADIATION SCIENCES 06-01 (2018) 01-11 Impact of the counts density of calibration image and the image reconstruction parameters in 131 I SPECT image quantification S. M. Carvalho
More informationFirst AUBMC Theranostics Conference: See What You Treat
The Division of Nuclear Medicine, PET/CT and Cyclotron Facilities, Department of Diagnostic Radiology, AUBMC presents the First AUBMC Theranostics Conference: See What You Treat Endorsed by the International
More informationHighlights from TC-IR
Highlights from TC-IR Ulrike Ankerhold, PTB TC-IR chair 10 th General Assembly, Plenary Session Oslo, Norway, 24 to 25 May 2016 Highlights from TC-IR Health EMRP projects (Health Call 2011; ended by April/May
More informationNuclear Regulatory Commission guidance on release of radioactive patients
Nuclear Regulatory Commission guidance on release of radioactive patients Dawn Banghart, CHP Sr. Health Physicist Alt. Radiation Safety Officer Nuc Med Can this therapy patient be released? Lu 177 Radioactive
More informationBrain Perfusion SPECT
APPROVED BY: Director of Radiology Page 1 of 5 Brain Perfusion SPECT Primary Indications: Brain perfusion SPECT is most commonly performed (1) to aid in identification of the epileptogenic focus in patients
More informationNuclear Medicine Head and Neck Region. Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine
Nuclear Medicine Head and Neck Region Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine Thyroid scintigraphy Parathyroid scintigraphy F18-FDG PET examinations in head and neck cancer
More informationINDICATIONS AND USAGE
1. INDICATIONS AND USAGE a) Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following
More informationQuantitative comparison of 124I PET/CT and 131I SPECT/CT detectability
Journal of Nuclear Medicine, published on October 22, 2015 as doi:10.2967/jnumed.115.162750 Quantitative comparison of 124I PET/CT and 131I SPECT/CT detectability Casper Beijst 1,2, Jakob W. Kist 3,4,
More informationRadionuclide Therapy: History, Present and Future Promise. History of Radionuclide (RN) Therapy. History of RN Therapy 8/2/2017
Radionuclide Therapy: History, Present and Future Promise Bennett S. Greenspan, MD, MS Professor, Dept. of Radiology, MCG / AU President, SNMMI AAPM Annual Meeting, Denver, CO History Symposium 8/02/2017
More informationFMU-ICRP Workshop on Radiological Protection in Medicine Current Status in Radionuclide Therapy Tuesday, October 3, 2017 Makoto Hosono, MD PhD Kindai
FMU-ICRP Workshop on Radiological Protection in Medicine Current Status in Radionuclide Therapy Tuesday, October 3, 2017 Makoto Hosono, MD PhD Kindai University Faculty of Medicine, Osaka, Japan Current
More informationPage 1 of CONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXUMIN safely and effectively. See full prescribing information for AXUMIN. AXUMIN (fluciclovine
More informationPET-CT for radiotherapy planning in lung cancer: current recommendations and future directions
PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions Gerry Hanna Centre for Cancer Research and Cell Biology Queen s University of Belfast @gerryhanna Talk Outline
More informationInternational Czech and Slovak cooperation in the treatment of patients with differentiated thyroid cancer
Nuclear Medicine Review 2006 Vol. 9, No. 1, pp. 84 88 Copyright 2006 Via Medica ISSN 1506 9680 International Czech and Slovak cooperation in the treatment of patients with differentiated thyroid cancer
More informationNuclear Medicine in the Diabetic Foot
26.11.2015, Uniklinik Balgrist Nuclear Medicine in the Diabetic Foot Martin Hüllner Nuklearmedizin und Neuroradiologie, USZ / UZH Outline A. Imaging modalities brief technical overview B. Nuclear medicine
More informationADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER
ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER Bro. Dr. Collie Miller IARC/WHO Based on trends in the incidence of cancer, the International Agency for Research on Cancer (IARC) and WHO
More informationAustin Radiological Association Nuclear Medicine Procedure BONE MINERAL STUDY (Tc-99m-MDP, Tc-99m-HMDP)
Austin Radiological Association Nuclear Medicine Procedure BONE MINERAL STUDY (Tc-99m-MDP, Tc-99m-HMDP) Overview The Bone Mineral Study, with either Tc-99m-MDP or Tc-99m-HMDP, depicts the distribution
More informationNuclear Sciences and Medicine
Nuclear Sciences and Medicine Rethy Chhem, MD, PhD (Edu), PhD (His), FRCPC Division of Human Health Guest Professor, Medical University of Vienna International Atomic Energy Agency Medical Imaging X-rays
More informationResearch Article Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration for Quality Control
BioMed Research International Volume 2015, Article ID 324708, 6 pages http://dx.doi.org/10.1155/2015/324708 Research Article Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration
More informationCT Optimisation for Paediatric SPECT/CT Examinations. Sarah Bell
CT Optimisation for Paediatric SPECT/CT Examinations Sarah Bell Sarah.bell14@nhs.net Outline 1. Introduction 2. Aims and Objectives 3. Methods 4. Results 5. Discussion 6. Conclusions 7. References Introduction
More informationNuclear Medicine in Australia. Shaun Jenkinson
Nuclear Medicine in Australia Shaun Jenkinson Landmark Infrastructure for Australian Science OPAL Research Reactor Australian Synchrotron Camperdown Cyclotron Bragg Institute Centre for Accelerator Science
More informationUnderstanding Biological Activity to Inform Drug Development
National Cancer Policy Forum Understanding Biological Activity to Inform Drug Development December 12, 2016 Wolfgang Weber Molecular Imaging and Therapy Service Department of Radiology RECIST Response
More informationThe value of 99m Tc-MAA SPECT/CT for lung shunt estimation in 90 Y radioembolization: a phantom and patient study
Allred et al. EJNMMI Research (2018) 8:50 https://doi.org/10.1186/s13550-018-0402-8 ORIGINAL RESEARCH Open Access The value of 99m Tc-MAA SPECT/CT for lung shunt estimation in 90 Y radioembolization: a
More informationY90 SIRT Therapy Dosimetric Aspects
Y90 SIRT Therapy Dosimetric Aspects David Chee-Eng Ng MBBS, BSc, MSc, MRCP, FAMS, FRCP (Edin) Head and Senior Consultant, Department of Nuclear Medicine and PET Singapore General Hospital Adjunct Assistant
More informationRole of IAEA in Promoting Nuclear Medicine
Section of Nuclear Medicine Division of Human Health Department of Sciences and Applications Role of IAEA in Promoting Nuclear Medicine Thomas NB Pascual Nuclear Medicine Section Is the world's centre
More informationNuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging
Nuclear Medicine in Thyroid Cancer Phillip J. Koo, MD Division Chief of Diagnostic Imaging Financial Disclosures Bayer Janssen Learning Objectives To learn the advantages and disadvantages of SPECT/CT
More informationAustin Radiological Association Nuclear Medicine Procedure SPHINCTER OF ODDI STUDY (Tc-99m-Mebrofenin)
Austin Radiological Association Nuclear Medicine Procedure SPHINCTER OF ODDI STUDY (Tc-99m-Mebrofenin) Overview Indications The successively demonstrates hepatic perfusion, hepatocyte clearance, hepatic
More informationIROC Prostate Phantom. Guidelines for Planning and Treating the IROC IMRT Prostate Phantom. Revised March 2014
IROC Prostate Phantom Guidelines for Planning and Treating the IROC IMRT Prostate Phantom. Revised March 2014 The study groups are requesting that each institution keep the phantom for a period of time
More informationPOSITRON EMISSION TOMOGRAPHY PHANTOM STUDIES FOR RADIATION THERAPY TARGET DELINEATION MICHAEL VINTSON LAWRENCE
POSITRON EMISSION TOMOGRAPHY PHANTOM STUDIES FOR RADIATION THERAPY TARGET DELINEATION BY MICHAEL VINTSON LAWRENCE A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL
More informationHaifeng Hou, 1,2,3,4 Shu Hu, 5 Rong Fan, 5 Wen Sun, 5 Xiaofei Zhang, 6 and Mei Tian 1,2,3,4. 1. Introduction
BioMed Research International Volume 2015, Article ID 974689, 4 pages http://dx.doi.org/10.1155/2015/974689 Clinical Study Prognostic Value of 99m Tc-Pertechnetate Thyroid Scintigraphy in Radioiodine Therapy
More informationEJNMMI Physics. Pedro L. Esquinas 1,2*, Ajit Shinto 3, Koramadai K. Kamaleshwaran 3, Jephy Joseph 3 and Anna Celler 1,2
Esquinas et al. EJNMMI Physics (2018) 5:30 https://doi.org/10.1186/s40658-018-0227-6 EJNMMI Physics ORIGINAL RESEARCH Open Access Biodistribution, pharmacokinetics, and organ-level dosimetry for 188 Re-AHDD-
More information2. RADIOPHARMACEUTICALS UTILIZED
1. OVERVIEW AND INDICATIONS (adapted from Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement, Version 3.0; reprinted from http://snmmi.files.cmsplus.com/docs/thyroid%20uptake%20measure%20v3%200.pdf,
More informationPre-clinical radionuclide therapy dosimetry in several pediatric cancer xenografts
DEPARTMENT OF Medical Physics UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH Pre-clinical radionuclide therapy dosimetry in several pediatric cancer xenografts Ian R. Marsh A. Besemer MS
More informationRadioiodine Therapy for Thyrotoxicosis (Hyperthyroidism)
Radioiodine Therapy for Thyrotoxicosis (Hyperthyroidism) Nuclear Medicine Patient information leaflet This leaflet contains some very important information for you and your family/partner please read the
More information